Epikast Secures Investment from Kos Biotechnology Partners

Epikast did not come out of a lab fantasy or a pitch deck fever dream. It came out of a very real frustration with how biopharma actually shows up in the world. Founded in 2021 and headquartered in New York with a serious operating backbone in Athens, Epikast looked at commercial, medical affairs, and patient engagement and asked why so much money was being burned to say so little. The answer became the business.

Dr. Vangelis Vergetis, PhD, CEO and co-founder, has spent his career bouncing between code, data, and the sharp end of healthcare reality. McKinsey taught him how the machine moves. Hakluyt showed him how influence really works. Intelligencia AI proved he could scale an AI platform across continents. At Epikast, he is building something less theoretical and more surgical, pairing technology with people who actually know the medicine.

The company’s model is simple in concept and brutal in execution. Seventy percent of the team holds an MD or PhD. These are Medical Science Liaisons, clinical specialists, patient case managers, and commercial operators working through a proprietary AI platform that measures engagement in real time. By running a credentialed hub out of Greece and deploying globally, Epikast delivers the same conversations at forty to fifty percent less cost, and does it in two to three months instead of half a year.

Epikast closed a Series A led by Kos Biotechnology Partners. The amount stays private, but the signal is loud. This is the inaugural investment for Kos, a €39 million life sciences fund purpose-built for platforms that can scale without pretending compliance is optional. As part of the round, Alex Tzoukas, Managing Partner and co-founder of Kos, joined the board, tightening the link between capital, execution, and long-term intent.

The board already carries weight. Dr. Stelios Papadopoulos, PhD, Chairman and co-founder, brings decades of biotech company building, from Exelixis to Anadys to Cellzome, plus years shaping capital markets from the inside. This is not ornamental governance. It is experience earned the hard way, now pointed at a market that is overdue for discipline and precision.

Epikast already works with multiple global top-ten pharmaceutical companies and a growing roster of biotech teams across the US and Europe. The platform is patented, the CEO is speaking on transparent AI at BIO, and the demand signal is clear. When budgets tighten and access shrinks, clarity becomes currency. Epikast is betting that the future of pharma engagement belongs to people who can speak medicine fluently, measure impact honestly, and move faster than tradition is comfortable with.